What is the appropriate treatment for a pregnant patient with hypertension and a blood pressure of 150/90 mm Hg?

Treatment of Hypertension in Pregnancy at 150/90 mmHg

For a pregnant patient with blood pressure of 150/90 mmHg, antihypertensive treatment should be initiated immediately with first-line agents (labetalol, methyldopa, or long-acting nifedipine), targeting a diastolic blood pressure of 85 mmHg and systolic blood pressure of 110-140 mmHg. 1

Treatment Threshold and Rationale

The blood pressure of 150/90 mmHg clearly meets treatment criteria across all major guidelines:

• Hypertension Canada (2020) recommends antihypertensive therapy for average systolic BP ≥140 mmHg or diastolic BP ≥90 mmHg in pregnant women with chronic hypertension, gestational hypertension, or preeclampsia 1

• The landmark CHAP trial (2022) demonstrated that treating mild chronic hypertension to a target of <140/90 mmHg reduced adverse pregnancy outcomes (30.2% vs 37.0% in untreated controls, P<0.001) without increasing risk of small-for-gestational-age infants 2

• International Society for the Study of Hypertension in Pregnancy (2018) recommends treatment for BP consistently ≥140/90 mmHg in clinic, targeting diastolic BP of 85 mmHg 3

This represents a shift from older guidelines that recommended treatment only at higher thresholds (≥150/95 mmHg or ≥160/110 mmHg) 4

First-Line Medication Options

Initial therapy should be monotherapy with one of the following first-line agents: 1

• Oral labetalol - β-blocker with α-blocking properties 1, 3
• Oral methyldopa - centrally acting α2-agonist, historically most studied in pregnancy 1, 3
• Long-acting oral nifedipine - calcium channel blocker 1, 3
• Other β-blockers (acebutolol, metoprolol, pindolol, propranolol) - acceptable alternatives 1

The CHAP trial primarily used labetalol or nifedipine with excellent safety profiles 2, 5

Target Blood Pressure

The treatment target should be: 1, 3

• Diastolic BP: 85 mmHg (Grade B evidence) 1
• Systolic BP: 110-140 mmHg 3
• Reduce or cease medications if diastolic BP falls <80 mmHg 3

The mean systolic BP achieved in the CHAP trial's active treatment group was 129.5 mmHg, demonstrating safety of this target 6

Medications to Add if Monotherapy Insufficient

If target BP is not achieved with standard-dose monotherapy, add a second agent from a different drug class: 1

Second-line options include: 1, 3

• Clonidine (centrally acting α2-agonist) 1
• Hydralazine (direct vasodilator) 1
• Thiazide diuretics 1

Absolutely Contraindicated Medications

The following medications are strictly contraindicated in pregnancy due to fetotoxicity: 1, 6, 7

• ACE inhibitors (enalapril, captopril, etc.) - cause fetal renal system damage 1, 6
• Angiotensin receptor blockers (ARBs) - fetotoxic effects similar to ACE inhibitors 1, 6
• Direct renin inhibitors - contraindicated 6, 4
• Spironolactone - should be avoided 6

Women planning pregnancy should be transitioned off these agents preconceptionally 1, 7

When This Becomes an Emergency

Blood pressure ≥160/110 mmHg constitutes an obstetrical emergency requiring urgent treatment in a monitored setting: 1, 3, 4

For severe hypertension, acceptable urgent treatment options include: 3, 8

• Oral nifedipine (10 mg, repeat every 20 minutes to maximum 30 mg) 8
• IV labetalol (20 mg bolus, then 40 mg after 10 minutes, then 80 mg every 10 minutes for 2 additional doses to maximum 220 mg) 8
• IV hydralazine (5 mg bolus, then 10 mg every 20-30 minutes to maximum 25 mg) 8

Essential Monitoring Requirements

For any pregnant patient on antihypertensive therapy, monitor for: 3

• Proteinuria assessment - screen with dipstick, quantify with protein/creatinine ratio if positive (≥30 mg/mmol is abnormal) 3
• Blood pressure monitoring - clinic measurements supplemented with home BP monitoring 3
• Laboratory tests (minimum twice weekly if preeclampsia): 3
  • Hemoglobin and platelet count
  • Liver function tests (transaminases)
  • Renal function (creatinine, uric acid)
• Clinical assessment for symptoms (headache, visual changes, right upper quadrant pain) 3
• Fetal monitoring - initial assessment of well-being, serial ultrasounds if growth restriction suspected 3

Critical Clinical Context

The type of hypertension matters for prognosis but not for initial treatment threshold at 150/90 mmHg: 1, 9

• Chronic hypertension - pre-existing before pregnancy or diagnosed <20 weeks gestation
• Gestational hypertension - new-onset after 20 weeks without proteinuria
• Preeclampsia - gestational hypertension with proteinuria or other organ dysfunction

All three conditions warrant treatment at BP ≥140/90 mmHg according to current evidence 1, 9

Evidence Strength and Recent Changes

The recommendation to treat at 140/90 mmHg (rather than waiting for higher thresholds) is supported by: 2, 10

• CHAP trial (2022) - largest randomized trial showing benefit of treating mild chronic hypertension, with number needed to treat of 14.7 to prevent one primary outcome event 2
• Meta-analysis (2023) - pooled data from 12 trials (4,461 women) showing treatment reduces severe hypertension (RR 0.53), preeclampsia (RR 0.71), placental abruption (RR 0.48), and neonatal mortality (RR 0.72) without increasing small-for-gestational-age births 10

This evidence has led ACOG and the Society for Maternal-Fetal Medicine to recommend treatment initiation at 140/90 mmHg for chronic hypertension in pregnancy 9, 5

Common Pitfalls to Avoid

• Do not withhold treatment waiting for "severe" hypertension - the CHAP trial definitively showed benefit of earlier intervention 2
• Do not use atenolol in early pregnancy - associated with fetal growth restriction 1
• Avoid methyldopa postpartum - risk of postnatal depression 4
• Do not combine nifedipine with magnesium sulfate without caution - risk of precipitous BP drop 8
• Do not use short-acting nifedipine - not FDA-approved for hypertension management 8